doi: 10.1186/s12951-014-0047-3, 33
If you cannot verify pharmacy license information or if the pharmacy is unwilling to provide it, consider this a major red flag
The trial was preregistered at ClinicalTrials.gov (NCT06309667) on February 14, 2024, and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines
SGLT2 vs Dual Agonists: Putting Weight Loss in Context SGLT2 inhibitors like empagliflozin (Jardiance) offer modest weight reduction of approximately 4 to 6 pounds, a fraction of what dual agonists deliver
This objective data tells you whether the medication is improving your metabolic health, which matters independently of weight loss
I started working in cardio like swimming (easier on my joints at first), biking, and pickleball